Bank of America just raised its EUR/USD forecast
ROCKVILLE, Md.—OS Therapies Inc. (NASDAQ:OSTX), a pharmaceutical company with a market capitalization of $87.5 million, recently saw a significant transaction as Einodmil LLC, a 10% owner of the company, sold shares amounting to a total of $112,609. The shares were sold at a weighted average price of $6.735 per share, with transactions occurring at prices ranging from $6.618 to $6.80 per share. According to InvestingPro data, the stock has experienced high volatility, with shares currently trading at $2.95.
The sale involved 16,720 shares of OS Therapies' common stock. Following this transaction, Einodmil LLC holds 2,531,211 shares indirectly, with Shalom Auerbach, the principal of Einodmil LLC, exercising voting and dispositive power over these shares. Auerbach has disclaimed beneficial ownership of the securities, except to the extent of his pecuniary interest.
This transaction highlights the ongoing activity in OS Therapies' stock, which is part of the pharmaceutical preparations industry. Investors will be watching closely to see how these changes in ownership might impact the company's market performance.
In other recent news, OS Therapies Inc, a biopharmaceutical company, has made significant advancements in its financial and clinical operations. The company has completed multiple private placements, raising a total of approximately $14.2 million. This includes a recent private placement that generated about $7.1 million and another that raised roughly $1.05 million. The funds are intended to reinforce the company's financial position and support its ongoing research and development initiatives.
Additionally, OS Therapies announced positive results from its Phase 2b clinical trial for OST-HER2, an immunotherapy candidate for recurrent lung metastatic osteosarcoma. The trial exhibited a promising 33.3% 12-month Event Free Survival rate for patients treated with OST-HER2. Interim analyses of the secondary endpoint, 3-year overall survival, also indicated a favorable trend for patients treated with the therapy.
These recent developments underline the company's commitment to its research and development efforts, particularly towards achieving clinical and regulatory milestones for OST-HER2. Analysts maintain an optimistic outlook for the company, with price targets ranging from $9 to $20 per share. As always, the company's financial activities and clinical trial results are disclosed in filings with the U.S. Securities and Exchange Commission, ensuring transparency for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.